Group 1 - The National Venture Capital Guidance Fund has officially launched, focusing on cutting-edge fields such as artificial intelligence, biopharmaceuticals, quantum technology, and 6G, with a lifespan of 15 to 20 years to match the long-term R&D needs of hard technology [2] - The fund aims to leverage a substantial fiscal investment to mobilize trillions in social capital, with at least 70% of investments directed towards seed and early-stage companies [2][3] - The fund operates as a "fund of funds," delegating decision-making to regional funds, which enhances efficiency and separates government guidance from market operations [2] Group 2 - Japan's new fiscal year budget is set at approximately 122.3 trillion yen (about $786 billion), marking a 6.3% increase from the previous year's budget [4] - The government plans to issue around 29.6 trillion yen in new bonds to support this budget, with a slight reduction in reliance on debt issuance [4][5] - The budget focuses on social security, debt repayment, and defense spending, reflecting the increasing financial pressures due to an aging population and rising costs [4][5] Group 3 - China's civil aviation sector is projected to achieve a record high of 770 million passenger trips in 2025, a 5.4% increase from 2024 and a 16.6% increase from 2019 [6] - The average economy class ticket price is expected to drop by 2.9% to 740 yuan, indicating a strategy of "price for volume" among airlines [6][7] - Despite the increase in passenger numbers, the low ticket prices are compressing profit margins, raising concerns about the sustainability of this pricing strategy [7] Group 4 - The robot rental market is experiencing explosive growth, with daily rental prices for basic intelligent robots dropping to around 200 yuan, while more advanced models range from 2,000 to 5,000 yuan [8] - The demand for robot rentals is high, with bookings extending into February, but prices are fluctuating significantly [8] - The market for humanoid robots is still in its early stages, and broader applications are needed for significant growth [9] Group 5 - The price of tomatoes has surged, with retail prices in many regions exceeding 10 yuan per jin, reflecting a nearly 71.9% year-on-year increase [10] - Adverse weather conditions have impacted supply, leading to higher prices during a seasonal transition period [10] - The demand for tomatoes is expected to rise further as the New Year and Spring Festival approach, maintaining upward pressure on prices [10] Group 6 - A report from Visa indicates that 28% of American adults would be pleased to receive cryptocurrency as a gift, with this figure rising to 45% among Gen Z [11] - Nearly half of shoppers have utilized AI tools for shopping tasks, highlighting the growing integration of technology in consumer behavior [11][12] - The rising inflation has made cryptocurrency a more appealing gift option, reflecting a shift in consumer preferences towards asset-based gifts [11] Group 7 - The LOF market has seen significant volatility, with multiple funds experiencing rapid price fluctuations, indicating potential irrational trading behavior [13] - The recent surge in silver prices has created arbitrage opportunities in the LOF market, but the risks associated with such trading strategies are evident [13] - The complexity of LOF products and the lack of transparency can lead to vulnerabilities for ordinary investors [13] Group 8 - The stock market experienced a slight increase, with the Shanghai Composite Index rising by 0.1% amid a volatile trading session [14] - Market sentiment showed signs of recovery after a brief dip, although many stocks turned from gains to losses [14] - The trading volume was substantial, indicating active market participation despite the fluctuations [14]

★ 宏观动态 ★ 工信部：加强算力网络体系建设，深入实施城域"毫秒用算"专项行动 12月25日至26日，全国工业和信息化工作会议在京召开。会议强调，2026年要围绕实现"十五五"良好开局，聚 焦重点、抓住关键，突出抓好十个方面重点工作。其中包括，推动信息通信业高质量发展。启动实施"宽带升 级"专项，开展新一轮万兆光网试点。加快移动物联网"万物智联"发展。加强算力网络体系建设，深入实施城 域"毫秒用算"专项行动。组织开展2026电信业务"明白办、放心用"行动。强化重要数据和核心数据识别与保 护，推动建立汽车等重点领域数据跨境流动机制。发布新版《无线电频率划分规定》，出台低空经济发展等领 域频率开发利用指南。 财政部：国家创业投资引导基金预计撬动万亿级社会资本 12月26日，国家创业投资引导基金启动仪式上，财政部相关负责人表示，国家创业投资引导基金具备以下新的 特点：一是财政力度更大；二是投资定位更精准，基金以"投早、投小、投长期、投硬科技"为鲜明导向，聚焦 人工智能、生物制药、量子科技、6G等前沿领域，以长达15年—20年的存续周期匹配硬科技、长周期的研发 需求；三是资金放大效果好。基金采取引导基金、区域基金、 ...

12月26日，国家创业投资引导基金正式启动，京津冀创业投资引导基金、长三角创业投资引导基金、粤 港澳大湾区创业投资引导基金三只区域基金设立运行，管理人分别由中金资本、国投创合和深创投担 任。 02 投 资定位更精准 基金以"投早、投小、投长期、投硬科技"为鲜明导向，聚焦人工智能、生物制药、量子科技、6G等前 沿领域，以长达15年至20年的存续周期匹配硬科技、长周期研发需求。 03 国家创业投资引导基金具备以下新的特点： 01 财政支持力度更大 国家创业投资引导基金使用超长期特别国债资金出资，在国家层面由财政出资1000亿元，发挥中央资金 引领带动作用。 采取市场化方式运作，由专业能力突出、综合实力强的管理机构负责区域基金具体投资。同时，相关部 门还将探索建立尽职免责机制和全生命周期考核机制，激发基金活力，鼓励基金着力长远、保持定力。 长三角创业投资引导基金 由国家级与沪苏浙皖多级国资联合出资，采用"子基金+直投项目"方式开展投资，聚焦人工智能、量子 科技、氢能储能、生物制造、具身智能、6G等前沿领域，全力支持原创性、颠覆性技术创新和关键核 心技术攻关，推动重大科技成果向现实生产力转化，服务国家高水平科技自立自 ...

【重点关注】 ·国家创业投资引导基金启动预计撬动万亿级社会资本 ·工信部：有序开展卫星物联网等新业务商用试验 ·预计降费超8亿元深交所推出2026年降费措施 ·市场监管总局开展规范光伏行业价格竞争秩序合规指导 ·现货白银价格一度突破每盎司75美元 【国内要闻】 ·12月26日，国家创业投资引导基金启动，京津冀创业投资引导基金、长三角创业投资引导基金、粤港 澳大湾区创业投资引导基金三只区域基金设立运行。财政部相关负责人表示，国家创业投资引导基金具 备以下新的特点：一是财政力度更大；二是投资定位更精准，基金以"投早、投小、投长期、投硬科 技"为鲜明导向，聚焦人工智能、生物制药、量子科技、6G等前沿领域，以长达15年—20年的存续周期 匹配硬科技、长周期的研发需求；三是资金放大效果好，基金采取引导基金、区域基金、子基金三层架 构，在区域基金及子基金层面，积极面向地方政府、金融机构、国有企业、民营企业等，通过千亿级财 政资金，预计将撬动万亿级的社会资本。 ·财政部等四部门发布《关于进一步发挥政府性融资担保体系作用加力支持就业创业的指导意见》，其 中指出，降低创业群体综合融资成本。鼓励有条件的地方在可持续经营的基础上， ...

来源：上海有色网 金属市场： 贵金属方面，截至15:08分，COMEX黄金涨0.86%，盘中最高冲至4561.6美元/盎司，继续刷新其上市以 来的历史新高；COMEX白银涨4.38%，盘中最高冲至75.495美元/盎司，同样刷新其历史高位。国内方 面，沪金涨0.75%，盘中最高冲至1023.96元/克的历史新高，沪银涨6.6%，盘中最高冲至18658元/千克， 同样刷新其历史记录！ 此外，铂主连涨9.29%，盘中一度封死涨停板，最高冲至其上市以来的历史新高709.85元/克，但临近收 盘涨幅略有收窄，最终收涨9.29%。钯主连跌2.08%。 截至今日15:08分行情 | 初始 代码 | | 省机 | ** | 最新 | 张帽% | 活跃跌 | 总置 | 现最 | 买入价 | 卖出价 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 3 | ecm | 欧线集运 干连 | 4 | 1824.5 | 0.61 | 11.0 | 2.66 万 | 2 | 1824.5 | 1825.0 | | 8 | CLOOY | NY ...

Group 1 - The core viewpoint of the news highlights the performance and growth of the Sci-Tech Innovation 100 Index and its ETF, indicating a positive trend in the market with a recent increase in both index and ETF values [1][3] - The Sci-Tech Innovation 100 Index ETF has seen a significant increase in its scale, reaching 6.158 billion yuan, marking a new high in the past month [3] - The ETF has experienced a notable inflow of funds, with a net inflow of 8.1815 million yuan recently, and a total of 140 million yuan over the last ten trading days [3] Group 2 - The National Venture Capital Guidance Fund has been launched, focusing on early-stage investments in hard technology sectors such as artificial intelligence, biopharmaceuticals, quantum technology, and 6G, with a long-term investment horizon of 15 to 20 years [1] - A strategic emerging industry development fund of 51 billion yuan has been initiated, targeting sectors like artificial intelligence, aerospace, high-end equipment, and future energy, which are expected to receive dual support from policies and funding [2] - The top ten weighted stocks in the Sci-Tech Innovation 100 Index account for 26.72% of the index, indicating a concentration in key companies such as Huahong Semiconductor and East China Semiconductor [3]

Summary of Key Points from Biotechnology Equity Research Conference Call Industry Overview - The report focuses on the biotechnology sector, specifically highlighting companies with significant potential for growth and upcoming catalysts in 2026. Key Companies and Their Outlook 1. **Dianthus Therapeutics, Inc. (DNTH)** - Market Cap: $1.82 billion - Price Target: $66 - Key catalysts include: - CIDP Phase III interim analysis in Q2 2026 - Initiation of gMG Phase III study in mid-2026 - Phase II MMN topline data in 2H26 - Potential for significant upside based on peak revenue estimates of ~$2 billion across neuromuscular diseases [19][20][24] 2. **Taysha Gene Therapies, Inc. (TSHA)** - Market Cap: $1.50 billion - Price Target: $11 - Focus on pivotal study for TSHA-102 in Rett syndrome with potential for a 6-month interim readout by YE26/1Q27 [26][27] 3. **Tyra Biosciences (TYRA)** - Market Cap: $1.36 billion - Price Target: $32 - Major catalysts include: - Phase III data for achondroplasia in early 2026 - Initial data for IR-NMIBC in 1H26 - Potential to disrupt the market with oral FGFR3 inhibitors [31][35] 4. **Tango Therapeutics, Inc. (TNGX)** - Market Cap: $1.15 billion - Price Target: $14 - Expected to show de-risking data for vopimetostat in combination with RVMD's RAS inhibitors in 2026 [37][40] 5. **ORIC Pharmaceuticals (ORIC)** - Market Cap: $783 million - Price Target: $23 - Key catalysts include dose-optimization data for prostate cancer and validating data from PFE's MEVPRO-1 trial [42][48] 6. **Solid Biosciences (SLDB)** - Market Cap: $463 million - Price Target: $15 - Focus on DMD program with key regulatory feedback expected in 1H26 [49][53] Major Catalysts and Events - **Upcoming Catalysts:** - RARE and MREO Phase III ORBIT final analysis expected in Dec'25/Jan'26 with potential stock movements of +100%/-30% [2] - ALNY, CRSP, and others expected to provide revenue guidance and business plans early in 2026 [1] - Regulatory events including FDA's Rare Disease Day on 2/23/26 [12] - **Drug Launches:** - Expected launches in 2026 include drugs from ALNY, ARWR, KALV, and others targeting various conditions [3] Financial Updates - **Price Target Changes:** - ARWR raised from $67 to $90 - KOD raised from $24 to $39 [6][10] Market Dynamics - **Pricing Stability:** - 2026 net pricing expected to remain stable with current Medicare contracts influencing high gross-to-net (GTN) guidance [12] - **Strategic Interest:** - Potential for M&A activity as companies like ORIC attract interest due to their prostate cancer programs [43] Conclusion - The biotechnology sector is poised for significant developments in 2026, with multiple companies presenting strong investment opportunities based on upcoming catalysts, drug launches, and strategic positioning in the market.

Group 1 - The visit of Chinese President Xi Jinping to South Korea marks a significant step in reaffirming the strategic partnership between China and South Korea, with both leaders agreeing to enhance cooperation in emerging fields such as artificial intelligence, biopharmaceuticals, green industries, and the silver economy [2][3] - The leaders emphasized the importance of maintaining a multilateral trade system and stable supply chains, which is crucial for South Korea's export-oriented economy [3][4] - The two countries aim to strengthen collaboration in areas like trade digitalization and green development, which aligns with their mutual interests in promoting inclusive growth [3][4] Group 2 - The establishment of the Korea-China Parliamentary Alliance in 2022, consisting of approximately 130 South Korean lawmakers, highlights the increasing people-to-people exchanges and the importance of youth engagement for the sustainable development of bilateral relations [5] - The focus on youth exchanges, including entrepreneurship and diplomatic interactions, is seen as vital for fostering closer ties between the two nations [5] - The ongoing cooperation and healthy competition between China and South Korea are expected to serve as a successful model for global governance [5]

中央经济工作会议在深入分析我国经济发展中的问题和挑战时指出，这些老问题新挑战大多是发展中、转型中的 问题，经过努力是可以解决的。会议强调，我国经济长期向好的支撑条件和基本趋势没有改变。要坚定信心、用 好优势、应对挑战，不断巩固拓展经济稳中向好势头。 中央经济工作会议还部署了"清理消费领域不合理限制措施""制定一体推进教育科技人才发展方案""实施新一轮重 点产业链高质量发展行动""推进教育资源布局结构调整"等重点任务，立足当前，着眼长远，都有进一步发挥优 势、释放潜力的鲜明导向。我们要落实好会议精神，真抓实干，把"四大优势"转化为发展胜势。 中国经济从来都是在风雨洗礼中发展、在历经考验中壮大。我们要深入贯彻落实习近平经济思想，坚定信念信心 不动摇，直面矛盾问题不回避，应对风险挑战不退缩，始终保持爱拼会赢的精气神，坚定不移办好自己的事，万 众一心、砥砺前行，奋力实现明年经济社会发展目标任务。 央视评论员 文章来源：央视网 责任编辑：左秋子 中央经济工作会议作出的判断，既直面经济发展中的风险挑战，又牢牢把握长期向好的基本趋势；既充分考量外 部环境变化的深层影响，又锚定国内发展的优势潜力；既传递出正视困难的理性分析， ...

Core Viewpoint - Huazhong Biopharmaceutical Company-B (02396) has successfully completed its IPO subscription, raising significant interest with an oversubscription rate of 594 times the public offering amount of HKD 90.02 million [1] Group 1: IPO Details - The IPO subscription period was from December 12 to December 17, with a total of HKD 53.6 billion in margin financing from brokers [1] - The company plans to issue 17.6488 million H-shares, with approximately 10% allocated for public offering and 90% for international offering, along with a 15% over-allotment option [1] - The share price is set between HKD 38.2 and HKD 51, with a minimum investment of HKD 10,302.9 for one lot of 200 shares, aiming to raise up to HKD 900 million [1] Group 2: Company Overview - Established in 2012, Huazhong Biopharmaceutical focuses on developing protein drugs for various therapeutic areas, particularly in wound healing therapies [1] - The company has two core products in its pipeline: Pro-101-1 for treating deep second-degree burns, which has completed IIb clinical trials, and Pro-101-2 for diabetic foot ulcers, currently in II phase clinical trials [2] Group 3: Market Position and Financials - As of the latest date, there are no approved PDGF products in the Chinese biopharmaceutical market, with Huazhong holding two of the three PDGF drug pipelines in the country [3] - The company has not yet commercialized any of its candidate products and has not generated any revenue from sales [3] - Financially, Huazhong reported net losses of RMB 105 million, RMB 212 million, and RMB 135 million for the fiscal years ending September 30 for 2023, 2024, and 2025, respectively, primarily due to R&D and administrative expenses [3] Group 4: Use of Proceeds - Approximately 61.8% of the net proceeds from the global offering will be allocated to the continued clinical development and commercialization of core products Pro-101-1 and Pro-101-2 [4] - About 18.8% will be used to enhance R&D capabilities through the purchase of specialized equipment and instruments [4] - The remaining proceeds will fund ongoing preclinical research for other PDGF products and operational expenses [4]